The Cancer Biomarker Conundrum: Too Many False Discoveries

The Cancer Biomarker Conundrum: Too Many False Discoveries
14 Aug 2010

"The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute...".cont'd including several references to ovarian cancer

FR Doc 2010-8386 Falsification of Data- complentary and alternative medicine NCCAM

U.S.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.

"...research  misconduct in research supported by National Center for Complementary
and Alternative Medicine (NCCAM), National Institutes of Health (NIH),
grant R01 AT001846 and Predoctoral Fellowship Award F31 AT003977-01,
and National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), NIH, grant R01 DK082773-01."

A Tweak to the Figures - falsifying data and figures

"The Scientist notes that the papers that include the falsified figures, which appeared in Endocrinology and Molecular Endocrinology, are in the process of being retracted. Writedit also reports that a former Wyeth researcher, Boris Cheskis, has accepted to a two-year agreement after Office of Research Integrity found that he falsified figures submitted to NIH."